Skip to content

Predicting ILD from Hypersensitivity Pneumonitis

Search Clinical Trials

Trial Objectives


Researchers believe they will be able to predict which patients with chronic Hypersensitivity Pneumonitis (HP) will develop interstitial lung disease (ILD) by looking at their genes and biomarkers in their blood. For this observational study, researchers will collect samples and data from participants with rapidly progressing HP and slowly progressing HP to look for patterns that can help predict the development of ILD and form specialized treatment plans.

Who Can Participate


Adults who have been diagnosed with Hypersensitivity Pneumonitis (HP).

Age: 18-90 Gender Any

Estimated Time Commitment


Clinic visits every 6 months over approximately 2 years (4 visits total)

Payment & Reimbursement


Payment Not Provided

Travel Reimbursement Not Available

Trial Contact


For more information, contact:

Elizabeth Del Real
303.398.1172

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


Investigator Initiated with funding from Boehringer Ingelheim

Principal Investigators

Evans Fernández

Evans Fernández, MD, MS

Co-Investigators

  • Tristan J. Huie

    Tristan J. Huie, MD

  • Rebecca C. Keith

    Rebecca C. Keith, MD

  • Lisa A. Maier

    Lisa A. Maier, MD, MSPH, FCCP

  • Michael P. Mohning

    Michael P. Mohning, MD

  • Joshua J. Solomon

    Joshua J. Solomon, MD

  • Zulma X. Yunt

    Zulma X. Yunt, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required